\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationThe Square and online
The registration for the European Research and Innovation Days (R&I Days) sixth edition, organised by the European Commission on 16 and 17 September 2025 (onsite in Brussels and online) is now open.
Since 2019 this event brings together policymakers, researchers, business leaders and the wider innovation community to discuss how research and innovation drives Europe’s competitiveness, sustainability and industrial leadership, underpinning the EU’s top priorities.
This year’s edition, “Together, towards a Research and Innovation Union”, will come at a pivotal moment of discussions on the EU’s next long-term budget and key policy actions such as the Startup and Scaleup Strategy, the European Life Sciences Strategy (more information on the consultation which closes on 17 April 2025 here), the AI in Science Strategy and the European Innovation and European Research Area Acts.
All information related to the R&I Days (programme, sessions, speakers, registration …) can be consulted in the run up to the event on this webpage. Subscription to their newsletter is possible here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
